Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/PF-184563> ?p ?o }
Showing triples 1 to 72 of
72
with 100 triples per page.
- PF-184563 abstract "PF-184563 is a potent, selective non-peptidic antagonist of the V1a receptor. The compound was discovered by Pfizer in its Sandwich, Kent research center, as a potential treatment for dysmenorrhoea, an indication for which V1a antagonists have shown efficacy.".
- PF-184563 atcPrefix "none".
- PF-184563 bioavailability "34.0".
- PF-184563 casNumber "748806-39-5".
- PF-184563 iupacName "8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene".
- PF-184563 thumbnail PF-184563.png?width=300.
- PF-184563 wikiPageID "33175636".
- PF-184563 wikiPageLength "2947".
- PF-184563 wikiPageOutDegree "7".
- PF-184563 wikiPageRevisionID "669035584".
- PF-184563 wikiPageWikiLink Arginine_vasopressin_receptor_1A.
- PF-184563 wikiPageWikiLink Category:Hormonal_agents.
- PF-184563 wikiPageWikiLink Category:Pfizer.
- PF-184563 wikiPageWikiLink Category:Vasopressin_receptor_antagonists.
- PF-184563 wikiPageWikiLink Dysmenorrhea.
- PF-184563 wikiPageWikiLink Dysmenorrhoea.
- PF-184563 wikiPageWikiLink Pfizer.
- PF-184563 wikiPageWikiLink Sandwich,_Kent.
- PF-184563 wikiPageWikiLinkText "PF-184563".
- PF-184563 atcPrefix "none".
- PF-184563 bioavailability "34.0".
- PF-184563 c "21".
- PF-184563 casNumber "748806".
- PF-184563 chembl "1837037".
- PF-184563 chemspiderid "9412479".
- PF-184563 cl "1".
- PF-184563 eliminationHalfLife "6480.0".
- PF-184563 h "23".
- PF-184563 hasPhotoCollection PF-184563.
- PF-184563 inchi "1".
- PF-184563 inchikey "LXHAZNJVVVBJIF-UHFFFAOYAV".
- PF-184563 iupacName "8".
- PF-184563 molecularWeight "394.91".
- PF-184563 n "6".
- PF-184563 proteinBound "69.0".
- PF-184563 smiles "CN1CC2=CN3CC1".
- PF-184563 stdinchi "1".
- PF-184563 stdinchikey "LXHAZNJVVVBJIF-UHFFFAOYSA-N".
- PF-184563 verifiedfields "changed".
- PF-184563 verifiedrevid "452024825".
- PF-184563 watchedfields "changed".
- PF-184563 width "220".
- PF-184563 wikiPageUsesTemplate Template:Drugbox.
- PF-184563 wikiPageUsesTemplate Template:Neuropeptidergics.
- PF-184563 wikiPageUsesTemplate Template:Reflist.
- PF-184563 wikiPageUsesTemplate Template:Systemic-hormonal-drug-stub.
- PF-184563 subject Category:Hormonal_agents.
- PF-184563 subject Category:Pfizer.
- PF-184563 subject Category:Vasopressin_receptor_antagonists.
- PF-184563 hypernym Antagonist.
- PF-184563 type Agent.
- PF-184563 type Article.
- PF-184563 type ChemicalSubstance.
- PF-184563 type Company.
- PF-184563 type Drug.
- PF-184563 type Agent.
- PF-184563 type Article.
- PF-184563 type Chemical.
- PF-184563 type Company.
- PF-184563 type Drug.
- PF-184563 type Preparation.
- PF-184563 type ChemicalObject.
- PF-184563 type Thing.
- PF-184563 type Q8386.
- PF-184563 comment "PF-184563 is a potent, selective non-peptidic antagonist of the V1a receptor. The compound was discovered by Pfizer in its Sandwich, Kent research center, as a potential treatment for dysmenorrhoea, an indication for which V1a antagonists have shown efficacy.".
- PF-184563 label "PF-184563".
- PF-184563 sameAs m.0h6927p.
- PF-184563 sameAs Q7119046.
- PF-184563 sameAs Q7119046.
- PF-184563 wasDerivedFrom PF-184563?oldid=669035584.
- PF-184563 depiction PF-184563.png.
- PF-184563 isPrimaryTopicOf PF-184563.